These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11363818)

  • 41. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Closing the circle on HIV--or not.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):10-4, 17-29 contd. PubMed ID: 11362964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
    J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on other antivirals.
    Cheng B
    PI Perspect; 1996 Apr; (no 18):7-8. PubMed ID: 11363513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. d4T and ddI shown to be safe and effective.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287. PubMed ID: 11361844
    [No Abstract]   [Full Text] [Related]  

  • 46. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
    Kline MW; Fletcher CV; Federici ME; Harris AT; Evans KD; Rutkiewicz VL; Shearer WT; Dunkle LM
    Pediatrics; 1996 Jun; 97(6 Pt 1):886-90. PubMed ID: 8657531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
    Moore RD; Wong WM; Keruly JC; McArthur JC
    AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ddI + d4T + IDV well tolerated in HIV-infected children.
    AIDS Patient Care STDS; 1997 Oct; 11(5):373. PubMed ID: 11361822
    [No Abstract]   [Full Text] [Related]  

  • 58. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
    Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD
    AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drug combination therapy for children infected with HIV/AIDS--own experience].
    Prandota-Schoepp A; Klinowska-Skupniewska J
    Przegl Epidemiol; 2001; 55 Suppl 3():135-41. PubMed ID: 11984940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.